Skip to content
Home
About Us
Longevity Platform
Bio101
BIO101 in Sarcopenia
BIO101 in Obesity
Biophytis Biopharmaceutical
Other Projects
Resources
Posters & Publications
Scientific Press Releases
Recruitment
Investors
Stock Information
Corporate Presentation
Letter to shareholders
Press Releases
General Meetings
AMF Regulated Information
SEC Filings
Convertible bonds
Pre-financed vouchers (PFW)
Obligations Hexagon
Obligations Hexagon
Contact for Investors
Contact
TNC FlipBook Classic items
2023-02-23_PR-AGM_30_March_EN
By
admin
November 1, 2025
2023-02-23_CP-AGM_30_mars_FR
By
admin
November 1, 2025
2023-03-09_CP_LungScienceConf_FR
By
admin
November 1, 2025
2023-03-01_PR_Exploit_Pharm
By
admin
November 1, 2025
2024_03_27_CP_Acces_Precoce_France_EN
By
admin
November 1, 2025
2023-03-20_CP_MDA
By
admin
November 1, 2025
2023-03-17_PR_ADR_ratio_change
By
admin
November 1, 2025
2023-03-17_CP_Changement_de_ration_ADR
By
admin
November 1, 2025
2023-03-09_PR_LungScienceConf_EN
By
admin
November 1, 2025
2023_03_31_CP_Convocation_2eAG
By
admin
November 1, 2025
โ
1
2
3
4
5
6
7
8
9
10
…
11
12
13
14
15
…
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
โ
Go to Top
Home
About Us
Longevity Platform
Bio101
BIO101 in Sarcopenia
BIO101 in Obesity
Biophytis Biopharmaceutical
Other Projects
Resources
Posters & Publications
Scientific Press Releases
Recruitment
Investors
Stock Information
Corporate Presentation
Letter to shareholders
Press Releases
General Meetings
AMF Regulated Information
SEC Filings
Convertible bonds
Pre-financed vouchers (PFW)
Obligations Hexagon
Obligations Hexagon
Contact for Investors
Contact
Home
About Us
Longevity Platform
Bio101
BIO101 in Sarcopenia
BIO101 in Obesity
Biophytis Biopharmaceutical
Other Projects
Resources
Posters & Publications
Scientific Press Releases
Recruitment
Investors
Stock Information
Corporate Presentation
Letter to shareholders
Press Releases
General Meetings
AMF Regulated Information
SEC Filings
Convertible bonds
Pre-financed vouchers (PFW)
Obligations Hexagon
Obligations Hexagon
Contact for Investors
Contact